LINKINVAX
LIVE

Serial Number

79333343

Owner

4A CONSULTING & ENGINEERING

Attorney

James C. Watson

Filing Date

Sep 16, 2021

Add to watchlist:

No watchlists yet
View on USPTO

LINKINVAX Trademark

Serial Number: 79333343 • Registration: 7064400

LINKINVAX is a trademark filed by 4A CONSULTING & ENGINEERING on September 16, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

4A CONSULTING & ENGINEERING (2 trademarks)

18 Chemin de la Vierge Noire

Entity Type: 34

LINKINVAX EUROPE (2 trademarks)

4 Rue Royale

Entity Type: 98

Trademark Details

Filing Date

September 16, 2021

Registration Date

May 30, 2023

Published for Opposition

March 14, 2023

Goods & Services

Pharmaceutical products for the treatment of infectious and parasitic diseases, diseases of viral or bacterial origin, dermatological diseases, metabolic diseases, endocrine diseases, eye diseases, ear, nose, and throat diseases, ear diseases, respiratory diseases, digestive system diseases, genito-urinary diseases, traumatic lesions, poisonings, cancers; vaccines; chemical preparations in the nature of medical preparations for medical use, namely, for the treatment of infectious and parasitic diseases, diseases of viral or bacterial origin, dermatological diseases, metabolic diseases, endocrine diseases, eye diseases, ear, nose, and throat diseases, ear diseases, respiratory diseases, digestive system diseases, genito-urinary diseases, traumatic lesions, poisonings, cancers; chemical preparations in the nature of pharmaceutical preparations for pharmaceutical use, namely, for the treatment of infectious and parasitic diseases, diseases of viral or bacterial origin, dermatological diseases, metabolic diseases, endocrine diseases, eye diseases, ear, nose, and throat diseases, ear diseases, respiratory diseases, digestive system diseases, genito-urinary diseases, traumatic lesions, poisonings, cancers

Pharmaceutical research and development; pharmaceutical research and development in the nature of research, development, engineering and testing in the fields of pharmaceutical products, medicines and vaccines; pharmaceutical research and development in the nature of testing, inspection, research and development of pharmaceutical preparations, medicines and vaccines; pharmaceutical research and development in the nature of research and development services for vaccines and medicines; scientific research and development in the field of biotechnology

Filing History

CHANGE OF OWNER RECEIVED FROM IB
Dec 27, 2024 CHLD
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 25, 2023 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Sep 1, 2023 FICS
FINAL DISPOSITION PROCESSED
Sep 1, 2023 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Aug 30, 2023 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
May 30, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
May 30, 2023 R.PR
NOTIFICATION PROCESSED BY IB
Mar 15, 2023 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 14, 2023 NPUB
PUBLISHED FOR OPPOSITION
Mar 14, 2023 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 22, 2023 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 22, 2023 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 22, 2023 NONP
WITHDRAWN FROM PUB - OG REVIEW QUERY
Jan 31, 2023 PBCR
APPROVED FOR PUB - PRINCIPAL REGISTER
Jan 13, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 12, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 12, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 12, 2023 TROA
REFUSAL PROCESSED BY IB
Aug 2, 2022 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jul 13, 2022 RFCS
REFUSAL PROCESSED BY MPU
Jul 13, 2022 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 23, 2022 RFCR
NON-FINAL ACTION WRITTEN
Jun 22, 2022 CNRT
ASSIGNED TO EXAMINER
Jun 21, 2022 DOCK
APPLICATION FILING RECEIPT MAILED
Feb 19, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Feb 15, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Feb 10, 2022 REPR